BELFAST HEALTH AND SOCIAL CARE TRUST
Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children: a Multi-centre Placebo Controlled Randomised Trial in the United Kingdom.
Short-sightedness, also called myopia, makes objects in the distance, such as the television, look blurred. This is caused by the eye growing too long, something that usually happens while children are also getting taller. People with myopia can see better with glasses or contact lenses, but this doesn’t stop their eyes continuing to become more short-sighted. This study is investigating a type of eye drop called atropine that might help to stop myopia getting worse as children get older. The aim of this study is to assess the effectiveness and safety of low dose atropine (0.01%) eye drops to reduce the progression of myopia in UK children.
The CHAMP Study was the last of our TRECA trials and so as with the others we produced the recruitment range of resources. This included a Patient Information Website with Animation and Video. We filmed the interviews at the School of Optometry at Aston University part of the Birmingham Children’s Hospital NHS Trust. There was as with other of these trials the requirement to produce more than one version of the information to match the patient information sheets, one for the target participant age group of 6 – 12 years and one for their parents. There is an obvious sticky button on the side of the site to enable users to switch between the two versions.